Se Joo Kim1, Daeyoung Roh1, Hyun Ho Jung1, Won Seok Chang1, Chan-Hyung Kim1, Jin Woo Chang1. 1. From the Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, South Korea (Se Joo Kim, Chan-Hyung Kim); the Department of Neurosurgery and Brain Research Institute, Yonsei University College of Medicine, Seoul, South Korea (Hyun Ho Jung, Won Seok Chang, Jin Woo Chang); and the Department of Psychiatry, Hallym University College of Medicine Clinical Imaging Research Centre, Chunchon, Gangwon, South Korea (Daeyoung Roh).
Abstract
BACKGROUND: Recently, a new thermal lesioning approach using magnetic resonance-guided focused ultrasound (MRgFUS) was introduced for the treatment of neurologic disorders. However, only 2 studies have used this approach for treatment-refractory obsessive-compulsive disorder (OCD), and follow-up was short-term. We investigated the efficacy and safety of bilateral thermal lesioning of the anterior limb of the internal capsule using MRgFUS in patients with treatment-refractory OCD and followed them for 2 years. METHODS: Eleven patients with treatment-refractory OCD were included in the study. Clinical outcomes were evaluated using the Yale-Brown Obsessive Compulsive Scale, the Clinical Global Impression scale (including improvement and severity), the Hamilton Rating Scale for Depression (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A) at 1 week and 1, 3, 6, 12 and 24 months following MRgFUS. Neuropsychological functioning, Global Assessment of Functioning and adverse events were also assessed. RESULTS: After MRgFUS, Yale-Brown Obsessive Compulsive Scale scores decreased significantly across the 24-month follow-up period (mean ± standard deviation, 34.4 ± 2.3 at baseline v. 21.3 ± 6.2 at 24 months, p < 0.001). Scores on the Hamilton rating scales for depression and anxiety also significantly decreased from baseline to 24 months (HAM-D, 19.0 ± 5.3 v. 7.6 ± 5.3, p < 0.001; HAM-A, 22.4 ± 5.9 v. 7.9 ± 3.9, p < 0.001). Global Assessment of Functioning scores improved significantly (35.8 ± 4.9 at baseline v. 56.0 ± 10.3 at 24 months, p < 0.001) and Memory Quotient significantly improved, but other neuropsychological functions were unchanged. The side effects of MRgFUS included headache and vestibular symptoms, but these were mild and transient. LIMITATIONS: The main limitations of this study were the small sample size and the open-label design. CONCLUSION: Bilateral thermal lesioning of the anterior limb of the internal capsule using MRgFUS may improve obsessive-compulsive, depressive and anxiety symptoms in patients with treatment-refractory OCD, without serious adverse effects.
BACKGROUND: Recently, a new thermal lesioning approach using magnetic resonance-guided focused ultrasound (MRgFUS) was introduced for the treatment of neurologic disorders. However, only 2 studies have used this approach for treatment-refractory obsessive-compulsive disorder (OCD), and follow-up was short-term. We investigated the efficacy and safety of bilateral thermal lesioning of the anterior limb of the internal capsule using MRgFUS in patients with treatment-refractory OCD and followed them for 2 years. METHODS: Eleven patients with treatment-refractory OCD were included in the study. Clinical outcomes were evaluated using the Yale-Brown Obsessive Compulsive Scale, the Clinical Global Impression scale (including improvement and severity), the Hamilton Rating Scale for Depression (HAM-D) and the Hamilton Rating Scale for Anxiety (HAM-A) at 1 week and 1, 3, 6, 12 and 24 months following MRgFUS. Neuropsychological functioning, Global Assessment of Functioning and adverse events were also assessed. RESULTS: After MRgFUS, Yale-Brown Obsessive Compulsive Scale scores decreased significantly across the 24-month follow-up period (mean ± standard deviation, 34.4 ± 2.3 at baseline v. 21.3 ± 6.2 at 24 months, p < 0.001). Scores on the Hamilton rating scales for depression and anxiety also significantly decreased from baseline to 24 months (HAM-D, 19.0 ± 5.3 v. 7.6 ± 5.3, p < 0.001; HAM-A, 22.4 ± 5.9 v. 7.9 ± 3.9, p < 0.001). Global Assessment of Functioning scores improved significantly (35.8 ± 4.9 at baseline v. 56.0 ± 10.3 at 24 months, p < 0.001) and Memory Quotient significantly improved, but other neuropsychological functions were unchanged. The side effects of MRgFUS included headache and vestibular symptoms, but these were mild and transient. LIMITATIONS: The main limitations of this study were the small sample size and the open-label design. CONCLUSION: Bilateral thermal lesioning of the anterior limb of the internal capsule using MRgFUS may improve obsessive-compulsive, depressive and anxiety symptoms in patients with treatment-refractory OCD, without serious adverse effects.
Authors: David Mataix-Cols; Lorena Fernández de la Cruz; Ashley E Nordsletten; Fabian Lenhard; Kayoko Isomura; Helen Blair Simpson Journal: World Psychiatry Date: 2016-02 Impact factor: 49.548
Authors: Pejman Ghanouni; Kim Butts Pauly; W Jeff Elias; Jaimie Henderson; Jason Sheehan; Stephen Monteith; Max Wintermark Journal: AJR Am J Roentgenol Date: 2015-07 Impact factor: 3.959
Authors: Christian Rück; Andreas Karlsson; J Douglas Steele; Gunnar Edman; Björn A Meyerson; Kaj Ericson; Håkan Nyman; Marie Asberg; Pär Svanborg Journal: Arch Gen Psychiatry Date: 2008-08
Authors: Lauren T Brown; Charles B Mikell; Brett E Youngerman; Yuan Zhang; Guy M McKhann; Sameer A Sheth Journal: J Neurosurg Date: 2015-08-07 Impact factor: 5.115
Authors: Pino Alonso; Daniel Cuadras; Loes Gabriëls; Damiaan Denys; Wayne Goodman; Ben D Greenberg; Fiacro Jimenez-Ponce; Jens Kuhn; Doris Lenartz; Luc Mallet; Bart Nuttin; Eva Real; Cinto Segalas; Rick Schuurman; Sophie Tezenas du Montcel; Jose M Menchon Journal: PLoS One Date: 2015-07-24 Impact factor: 3.240
Authors: Hongchae Baek; Daniel Lockwood; Emily Jo Mason; Emmanuel Obusez; Matthew Poturalski; Richard Rammo; Sean J Nagel; Stephen E Jones Journal: Front Neurol Date: 2022-05-09 Impact factor: 4.086
Authors: Benjamin Davidson; Clement Hamani; Ying Meng; Anusha Baskaran; Sachie Sharma; Agessandro Abrahao; Margaret Anne Richter; Anthony Levitt; Peter Giacobbe; Nir Lipsman; Jennifer S Rabin Journal: Transl Psychiatry Date: 2020-11-11 Impact factor: 6.222